Stocks

Eli Lilly buys Orna Therapeutics for $2.4B, boosting its drug pipeline. A big bet on future returns.

ETH dips to $2K despite $7.5K 2026 target. Bears eye $1.7K, but institutions see long-term gains.

HYPE rallies 41.5% on utility & reduced unlocks, decoupling from BTC. Ripple partnership adds fuel.

Russell 2000 beats S&P 500 by 6% as small caps show strong earnings & revisions. Valuations rise.

SBCFX joins Financial Commission, offering clients up to €20k dispute protection. Risk management enhanced.

Tesla Semi gets $165M in CA subsidies despite unproven tech & delayed timeline. Critics cry market distortion.

NXPI beats Q4 estimates, but inventory woes loom. FY26 EPS seen up 21.3%, with 15.8% avg upside target.